CD3×GPRC5D bispecific antibody that redirects T cells to kill GPRC5D-expressing myeloma cells.
Humanized bispecific antibody that binds CD3 on T cells and GPRC5D on myeloma cells, bringing them into proximity to activate cytotoxic T cells and mediate targeted lysis of GPRC5D-expressing tumor cells.
YES
DIRECT
Talquetamab bridges CD3 on T cells to GPRC5D on target cells, activating T cells to form an immune synapse and kill GPRC5D+ cells via perforin/granzyme-mediated cytolysis (and related apoptotic pathways).
CD3×GPRC5D bispecific antibody that redirects T cells to kill GPRC5D-expressing myeloma cells.
Humanized bispecific antibody that binds CD3 on T cells and GPRC5D on myeloma cells, bringing them into proximity to activate cytotoxic T cells and mediate targeted lysis of GPRC5D-expressing tumor cells.
NO
INDIRECT
Talquetamab binds CD3 on T cells and GPRC5D on tumor cells to activate T-cell cytotoxicity (perforin/granzyme) against GPRC5D-expressing cells; CD3+ T cells are not the killed target.
Anti-CD38 monoclonal antibody mediating ADCC, CDC, and apoptosis of CD38+ plasma cells.
Human IgG1κ anti-CD38 monoclonal antibody that binds CD38 on plasma cells and other immune cells, inducing tumor cell death via ADCC, ADCP, CDC, and direct apoptosis; also depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs), enhancing antitumor immunity.
YES
DIRECT
Daratumumab binds CD38 on target cells and induces NK-cell ADCC, macrophage ADCP, complement-mediated CDC, and can trigger direct apoptosis, depleting CD38+ cells.
Bispecific TCR/CD3 ImmTAC that targets gp100/HLA-A*02:01 and engages CD3 to redirect T cells to gp100-positive melanoma cells.
ImmTAC consisting of a high‑affinity TCR specific for the gp100 peptide presented by HLA‑A*02:01 fused to an anti‑CD3 scFv; binds gp100/HLA‑A*02:01 on melanoma cells and CD3 on T cells to redirect and activate polyclonal T cells, leading to CTL-mediated killing of gp100‑positive tumor cells.
YES
DIRECT
Tebentafusp binds gp100 peptide presented by HLA-A*02:01 on target cells and CD3 on T cells, recruiting and activating T cells to kill the bound cells via perforin/granzyme-mediated cytotoxicity (apoptosis).
Bispecific TCR/CD3 ImmTAC that targets gp100/HLA-A*02:01 and engages CD3 to redirect T cells to gp100-positive melanoma cells.
ImmTAC consisting of a high‑affinity TCR specific for the gp100 peptide presented by HLA‑A*02:01 fused to an anti‑CD3 scFv; binds gp100/HLA‑A*02:01 on melanoma cells and CD3 on T cells to redirect and activate polyclonal T cells, leading to CTL-mediated killing of gp100‑positive tumor cells.
NO
INDIRECT
CD3-expressing T cells are not killed; tebentafusp binds CD3 to activate and redirect T cells to gp100/HLA-A*02:01–positive tumor cells, which are then lysed by T-cell cytotoxicity (perforin/granzyme).